RNA-sequencing of shSRC-1 and shNT tamoxifen treated LY2 cells

The steroid co-activator protein SRC-1 plays an important role in endocrine therapy resistant breast cancer. Its expression is associated with large high grade tumours, HER2 positivity, disease recurrence and resistance to endocrine therapy. SRC-1''s role in affecting the transcriptome of the breast cancer endocrine resistant setting is uncovered through this RNA-seq analysis of LY2 cells grown with or without the presence of SRC-1 Overall design: We report the RNA-sequencing of tamoxifen treated LY2 breast cancer cells treated with non-targeting shRNA or SRC-1 (NCOA1) targeting shRNA and examine the gene expression differences.